Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 2/20 | 0.52 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.52 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.52 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | NAMPT | P43490 | 5/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30666248 | 1.00 | SMARCA2 (0.52) | SMARCA2SMARCA4PBRM1SCD5GPR119 | |
| SCHEMBL27172162 | 0.86 | SMARCA2 (0.52) | SMARCA2SMARCA4PBRM1GPR119NAMPT | |
| SCHEMBL26683270 | 0.82 | GPR119 (0.40) | SCD5GPR119NAMPTCYP2C9 | |
| SCHEMBL30666220 | 0.82 | GPR119 (0.40) | SCD5GPR119NAMPTCYP2C9 | |
| SCHEMBL26683498 | 0.78 | SMARCA2 (0.52) | SMARCA2SMARCA4PBRM1SCD5GPR119 | |
| SCHEMBL30666247 | 0.78 | SMARCA2 (0.52) | SMARCA2SMARCA4PBRM1SCD5GPR119 | |
| SCHEMBL26683624 | 0.78 | PBRM1 (0.41) | SMARCA2SMARCA4PBRM1 | |
| SCHEMBL30666266 | 0.78 | SMARCA2 (0.48) | SMARCA2SMARCA4PBRM1SCD5GPR119 | |
| SCHEMBL26683411 | 0.78 | SMARCA2 (0.48) | SMARCA2SMARCA4PBRM1SCD5GPR119 | |
| SCHEMBL30666234 | 0.75 | SMARCA2 (0.56) | SMARCA2SMARCA4PBRM1GPR119NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304596-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304596-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | VHL, BRCA1, SF3B5 | SMARCA2 67/4885SMARCA4 22/4885PBRM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.